Skip to content

Bristol-Myers Squibb Psoriasis (abatacept)

Psoriatic arthritis (PsA) is a chronic inflammatory disease affecting about 6-10 of patients with cutaneous psoriasis. Bristol-Myers Squibb, Orencia (Abatacept) Product Monograph, Bristol-Myers Squibb. The PAUSE study is testing the combination of two biologics, ustekinumab (Janssen Biotech, Inc.) and abatacept (Bristol-Myers Squibb), in psoriasis patients. Activated T-cells are present in inflamed joints of patients with psoriasis. Abatacept (Orencia, Bristol-Myers Squibb), a new biologic agent indicated for use as a first-line treatment for rheumatoid arthritis, effectively inhibits T-cell co-stimulation by blocking the interaction of lymphocyte function-associated antigen 3 (LFA-3) with CD2.

Bristol-Myers Squibb Psoriasis (abatacept) 2Biologic. Immunoscience. Belatacept. NULOJIX. M. Biologic. Immunoscience. Anti-CD40. 1. Biologic. Immunoscience. Abatacept. ORENCIA. Subjects in BMS study number IM101075 received either abatacept or placebo on a background of mycophenolate mofetil and corticosteroids. Technology evaluation: Abatacept, Bristol-Myers Squibb. Grant/Research/Clinical Trial Support: Amgen Psoriasis (Etanercept, brodalumab); Pfizer Psoriasis (tofacitinib); Bristol-Myers Squibb Psoriasis (abatacept);

Abatacept (Orencia, Bristol-Myers Squibb Company, Princeton, NJ) is a selective costimulation modulator which inhibits T cell (T lymphocyte) activation. Abatacept is considered investigational and not medically necessary for all other indications, including, but not limited to the treatment of: ankylosing spondylitis, Crohn’s disease, giant cell arteritis and Takayasu’s arteritis, graft versus host disease (GVHD), lupus nephritis, multiple sclerosis, psoriatic arthritis, psoriasis vulgaris, scleroderma, systemic lupus erythematosus, type 1 diabetes, ulcerative colitis, and uveitis. Arthritis Int Med Assoc LLC, Trumbull, CT Bristol-Myers Squibb, Princeton, NJ Bristol-Myers Squibb, Pennington, NJ Bristol-Myers Squibb, Doylestown, PA Schoen Klinik, Hamburg, Germany Seattle Rheumatology Associate, Seattle, WA Stanford University, Sunnyvale, CA. It is unclear whether the sponsor, Bristol-Myers Squibb, will seek approval to market abatacept specifically for psoriatic arthritis. Five of the 13 authors listed Bristol-Myers Squibb as their affiliation, but otherwise there was no disclosure statement for this online report.

Abatacept

Bristol-Myers Squibb Psoriasis (abatacept) 3Abatacept (Orencia, Bristol Myers Squibb) has been on the market for rheumatology as Orencia for a number of years and is moving into the psoriasis disease space. Oaks Feldman SR, Krueger GG (2005) Psoriasis assessment tools in clinical trials. Abatacept (marketed as Orencia) is a fusion protein composed of an immunoglobulin fused to the extracellular domain of CTLA-4, a molecule capable of binding B7. It was developed by Bristol-Myers-Squibb and is licensed in the United States for the treatment of rheumatoid arthritis in the case of inadequate response to anti-TNFa therapy. (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis. Novartis, Boehringer and Celgene present new psoriasis data at AAD meeting23-03-2015. Bristol-Myers Orencia equals Humira in head-to-head AMPLE RA study12-06-2013. Otezla (apremilast); Celgene; For the treatment of adults with active psoriatic arthritis, Approved March 2014. Orencia (abatacept); Bristol-Myers Squibb; For the treatment of Juvenile Idiopathic Arthritis, Approved April 2008. Bristol-Myers Squibb Psoriatic arthritis Molecule CTLA-4Ig CTLA-4Ig.

Abatacept

Abatacept (marketed as Orencia) is drug used to treat autoimmune diseases like rheumatoid arthritis, by interfering with the immune activity of T cells. Abatacept was developed by Bristol-Myers Squibb and is licensed in the United States for the treatment of rheumatoid arthritis in the case of inadequate response to anti-TNF therapy.